13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001839435
Total reported value
$1.1B
$1.1B
26 檔
29.7%
As reported in its official Q3 2025 Form 13F filing, Octagon Capital Advisors LP's tracked investment portfolio stood at $1.1B with 26 total positions.
In Q3 2025, Octagon Capital Advisors LP adopted a defensive or profit-taking posture, trimming 13 positions and completely liquidating 15 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | Stock-Other | 17.05% | +3.55% | +4.58% | |
| 2 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 14.41% | -1.94% | +3.20% | |
| 3 | GOSS | Gossamer Bio Inc | Stock-Other | 6.80% | -0.17% | -7.08% | |
| 4 | COGT | Cogent Biosciences Inc | Stock-Other | 6.26% | -1.84% | +4.02% | |
| 5 | AVBP | Arrivent Biopharma Inc | Stock-Other | 5.51% | +1.12% | +1.28% | |
| 6 | OCUL | Ocular Therapeutix Inc | Stock-Other | 4.65% | -1.14% | +8.21% | |
| 7 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 4.49% | +1.55% | -27.99% | |
| 8 | ✓ | Merus N V | Stock-Other | 4.40% | — | -20.82% | |
| 9 | CDTX | Cidara Therapeutics Inc | Stock-Other | 4.35% | — | — | |
| 10 | TRVI | Trevi Therapeutics Inc | Stock-Other | 3.90% | -1.43% | -23.34% | |
| 11 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 3.81% | — | — | |
| 12 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 3.10% | — | — | |
| 13 | KYMR | Kymera Therapeutics Inc | Stock-Other | 3.09% | -0.72% | +35.34% | |
| 14 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.05% | -3.30% | EXIT | |
| 15 | PHVS | Pharvaris N.V. | Stock-Other | 2.73% | +0.90% | +7.43% | |
| 16 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 2.35% | -3.23% | EXIT | |
| 17 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 2.14% | — | — | |
| 18 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 1.83% | -0.71% | EXIT | |
| 19 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 1.54% | -0.48% | — | |
| 20 | NUVB | Nuvation Bio Inc | Stock-Other | 1.48% | — | -65.76% | |
| 21 | MAZE | Maze Therapeutics Inc | Stock-Other | 0.70% | — | — | |
| 22 | NGNE | Neurogene Inc | Stock-Other | 0.66% | — | -16.83% | |
| 23 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 0.66% | -0.31% | — | |
| 24 | PEPG | Pepgen Inc | Stock-Other | 0.49% | — | — | |
| 25 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.49% | — | — | |
| 26 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.06% | — | -32.44% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | +15.6% | +4.58% | Add |
| 2 | DNTH | Dianthus Therapeutics Inc | +6.2% | +3.20% | Add |
| 3 | COGT | Cogent Biosciences Inc | +3.1% | +4.02% | Add |
| 4 | GOSS | Gossamer Bio Inc | +2.9% | -7.08% | Trim |
| 5 | ✓ | Merus N V | +1.9% | -20.82% | Unchanged |
| 6 | TSHA | Taysha Gene Therapies Inc | +1.6% | -27.99% | Trim |
| 7 | OCUL | Ocular Therapeutix Inc | +1.2% | +8.21% | Add |
| 8 | CRBP | Corbus Pharmaceuticals Holdi | +1% | — | Unchanged |
| 9 | BRD1EUR | Mind Medicine Mindmed Inc | +0.4% | — | Trim |
| 10 | PHVS | Pharvaris N.V. | +0.4% | +7.43% | Trim |
| 11 | NGNE | Neurogene Inc | 0% | -16.83% | Trim |
| 12 | TRVI | Trevi Therapeutics Inc | -0.1% | -23.34% | Trim |
| 13 | MAZE | Maze Therapeutics Inc | -0.3% | — | Trim |
| 14 | 4XC1 | Kalvista Pharmaceuticals Inc | -0.7% | — | Trim |
| 15 | NUVB | Nuvation Bio Inc | -1.2% | -65.76% | Trim |
| 16 | AVBP | Arrivent Biopharma Inc | -1.9% | +1.28% | Trim |
| 17 | 260 | Centessa Pharmaceuticals-adr | -2.6% | -19.42% | Trim |
| 18 | APLSUSD | Apellis Pharmaceuticals Inc | -5.8% | — | Trim |
| 19 | NUVB-WS | Nuvation Bio Inc -cw27 | -9.3% | -32.44% | Trim |
| 20 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 21 | KYMR | Kymera Therapeutics Inc | — | NEW | New buy |
| 22 | VRNA | Verona Pharma PLC - Adr | — | EXIT | Sold out |
| 23 | TRML | Tourmaline Bio Inc | — | EXIT | Sold out |
| 24 | BBOT | Bridgebio Oncology Therapeut | — | NEW | New buy |
| 25 | MLTX | Moonlake Immunotherapeutics | — | EXIT | Sold out |
| 26 | SNDX | Syndax Pharmaceuticals Inc | — | EXIT | Sold out |
| 27 | ATYR | Atyr Pharma Inc | — | EXIT | Sold out |
| 28 | SRRK | Scholar Rock Holding CORP | — | EXIT | Sold out |
| 29 | VSTM | Verastem Inc | — | EXIT | Sold out |
| 30 | DBVT | Dbv Technologies Sa-spon Adr | — | NEW | New buy |
| 31 | RGLS | Regulus Therapeutics Inc | — | EXIT | Sold out |
| 32 | SPRY | Ars Pharmaceuticals Inc | — | EXIT | Sold out |
| 33 | ERAS | Erasca Inc | — | EXIT | Sold out |
| 34 | VRDN | Viridian Therapeutics Inc | — | EXIT | Sold out |
| 35 | ✓ | — | EXIT | Sold out | |
| 36 | CATX | Perspective Therapeutics Inc | — | EXIT | Sold out |
| 37 | UNCY | Unicycive Therapeutics Inc | — | NEW | New buy |
| 38 | KLRS | Kalaris Therapeutics Inc | — | EXIT | Sold out |
| 39 | PEPG | Pepgen Inc | — | NEW | New buy |
| 40 | GPCR | Structure Therapeutics Inc | — | NEW | New buy |
| 41 | ✓ | Helix Acquisition CORP Ii | — | EXIT | Sold out |
According to official SEC Form 13F filings, Octagon Capital Advisors LP reported a total U.S. public equity portfolio value of $1.1B across 26 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ABVX, DNTH, GOSS) accounted for 29.7% of total reported equity market value during Q3 2025.
Top New Position Initiated
CDTX
市值: $28.7M
Top Position Liquidated / Trimmed
VRNA
前期市值: $13.8M
During Q3 2025, Octagon Capital Advisors LP's top holdings by market value included ABVX (17.1%)、DNTH (14.4%)、GOSS (6.8%). The largest single position, ABVX, represented 17.1% of total portfolio value.
In Q3 2025, Octagon Capital Advisors LP made 39 total portfolio adjustments, initiating 7 new buys, adding to 4 positions, trimming 13 holdings, and fully liquidating 15 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.